Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission
Status:
Not yet recruiting
Trial end date:
2026-07-30
Target enrollment:
Participant gender:
Summary
This trial is a single-center, single-arm, prospective clinical study to investigate the
efficacy and safety of zanubrutinib maintenance therapy in patients with diffuse large B-cell
lymphoma (DLBCL) in Initial remission. The patients were divided into two categories: 1)
Zanubrutinib maintenance therapy was started after R-CHOP induction and consolidation therapy
reached maximum efficacy; 2) Initiate zanubrutinib maintenance therapy after maximal response
to induction and consolidation therapy with or without rituximab (R-chemo). Therefore, the
data in this study will reflect the efficacy and safety of zanubrutinib in the maintenance
treatment of DLBCL patients with initial remission, and will provide new insights into the
clinical application of zanubrutinib.